HPV vaccine may stop precancerous lesions from returning
NCT ID NCT07431502
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive either the vaccine or a placebo. The goal is to see if vaccination reduces the chance of a new HSIL at the same site.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 984 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women, men, transgender,18 ≤age ≤55 * ECOG performance status ≤ 1 * Patients infected with HIV are eligible for the study provided they are receiving antiretroviral therapy with undetectable viral load. * Biopsy-proven HPV related HSIL at any site (vulvar VIN, vaginal VaIN, cervical CIN, anal AIN, penile PeIN) at baseline. * Women of childbearing potential must have a negative urine pregnancy test 24 hours prior to the administration of the first vaccine injection. * Sexually active patients must agree to use acceptable and appropriate contraception while included in BIO-HPV study and until the last dose of vaccine. * Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. * Patients must be affiliated to a social security system or beneficiary of the same * Life expectancy of greater than 5 years Exclusion Criteria: * History of HPV related cancer (i.e. anal, genital, head and neck, cutaneous, penile) * History of prior treatment of HSIL * Warts so extensive that they preclude the clinician from determining the extent and location of HSIL Prior HPV vaccination * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 21 days prior to the first dose of trial treatment. * Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of study treatment. * Prior malignancy active within the previous 3 years except from cancers with an expected PFS at 5 years of \>95%. * Hypersensitivity to the active substances or to any of the excipients (Listed in the SmPC). * Acute or severe febrile illness. Vaccination must be postponed until the individual has fully recovered. * Pregnant women or intent to become pregnant * Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anal high grade squamous intraepithelial lesion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.